



Publication of a Transparency Notification Received from Alychlo

Liege, Belgium, 25 February 2022 – 7:35 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 24 February 2022.

Alychlo NV has notified Mithra that it has dropped below the 10% legal threshold on 18 February 2022, following the temporary share loan related to the exercise by the Company of a first drawing request on 4 February 2022 under the equity funding agreement with Goldman Sachs International¹. Alychlo NV now holds 9,32% (4,144,730 shares) of the 44,493,450 shares currently outstanding. Previously, Alychlo NV held 11% of the 49,894,736 shares outstanding.

The detailed transparency notifications are available on the [Investors website](#) of Mithra. An updated overview of the Mithra's shareholders structure will be included in the corporate governance charter of Mithra, which will be made available on its website.

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.

www.mithra.com

¹ [Mithra's press release 07/02/2022](#)

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

A circular teal icon with the text "News Alerts" in white, bold, sans-serif font.

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)